News coverage about Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) has trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novelion Therapeutics earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.7431429106585 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Several research analysts have recently commented on the stock. ValuEngine lowered shares of Novelion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 12th. Royal Bank of Canada dropped their price target on shares of Novelion Therapeutics from $9.00 to $8.00 and set a “sector perform” rating on the stock in a research note on Friday, November 10th. Finally, Zacks Investment Research lowered shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th.

Shares of Novelion Therapeutics (NASDAQ NVLN) traded down $0.07 on Friday, hitting $3.41. 83,900 shares of the stock traded hands, compared to its average volume of 99,446. Novelion Therapeutics has a 52 week low of $3.25 and a 52 week high of $12.12. The company has a current ratio of 1.45, a quick ratio of 1.28 and a debt-to-equity ratio of 6.53.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Novelion Therapeutics (NVLN) Share Price” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/12/15/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-novelion-therapeutics-nvln-share-price.html.

Novelion Therapeutics Company Profile

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Insider Buying and Selling by Quarter for Novelion Therapeutics (NASDAQ:NVLN)

Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.